AXA Framlington Biotech Fund GBP Z AccRegister to Unlock Ratings |
Performance History | 30/04/2022 |
Growth of 1,000 (GBP) | Advanced Graph |
![]() | Fund | -6.4 | 19.4 | 32.7 | 3.4 | -12.2 |
![]() | +/-Cat | 1.5 | -0.8 | 6.8 | 12.4 | 4.3 |
![]() | +/-B’mrk | -3.2 | -0.9 | 10.2 | 2.4 | 1.8 |
Category: Sector Equity Biotechnology | ||||||
Category Benchmark: NASDAQ Biotechnology TR USD |
Key Stats | ||
NAV 20/05/2022 | GBX 415.20 | |
Day Change | 2.57% | |
Morningstar Category™ | Sector Equity Biotechnology | |
IA (formerly IMA) Sector | Specialist | |
ISIN | GB00B784NS11 | |
Fund Size (Mil) 30/04/2022 | GBP 385.20 | |
Share Class Size (Mil) 20/05/2022 | GBP 289.82 | |
Max Initial Charge | - | |
Ongoing Charge 21/09/2021 | 0.83% |
Investment Objective: AXA Framlington Biotech Fund GBP Z Acc |
The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Linden Thomson 05/07/2012 | ||
Peter Hughes 01/04/2018 | ||
Inception Date 16/04/2012 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | NASDAQ Biotechnology TR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for AXA Framlington Biotech Fund GBP Z Acc | 31/03/2022 |
|
|
Top 5 Holdings | Sector | % |
![]() | ![]() | 8.57 |
![]() | ![]() | 5.13 |
![]() | ![]() | 4.78 |
![]() | ![]() | 4.57 |
![]() | ![]() | 4.52 |
![]() | ||
![]() ![]() ![]() | ||
AXA Framlington Biotech Fund GBP Z Acc |